CNS Pharmaceuticals, Inc. SEC filings CNSP
CNS Pharmaceuticals, Inc. has 390 filings in SEC EDGAR's recent list, going back to Mar 13, 2018. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 2, 2026 (officer or director change, shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 26, 2026 | — |
| CORRESP | Letter to the SEC | May 22, 2026 | — |
| UPLOAD | Letter from the SEC | May 22, 2026 | — |
| D | Filing | May 19, 2026 | — |
| EFFECT | Filing | May 13, 2025 | — |
| CORRESP | Letter to the SEC | May 12, 2025 | — |
| CORRESP | Letter to the SEC | May 12, 2025 | — |
| CORRESP | Letter to the SEC | Apr 17, 2025 | — |
| CORRESP | Letter to the SEC | Apr 17, 2025 | — |
| CORRESP | Letter to the SEC | Apr 14, 2025 | — |
| CORRESP | Letter to the SEC | Apr 14, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 11, 2025 | — |
| DRSLTR | Filing | Apr 7, 2025 | — |
| DRS | Filing | Apr 7, 2025 | — |
| DEFR14A | Definitive revised proxy soliciting materials | Nov 15, 2024 | — |
| EFFECT | Filing | Aug 2, 2024 | — |
| RW | Request for withdrawal | Jul 31, 2024 | — |
| EFFECT | Filing | May 17, 2024 | — |
| CORRESP | Letter to the SEC | May 15, 2024 | — |
| UPLOAD | Letter from the SEC | May 15, 2024 | — |
| EFFECT | Filing | Jan 29, 2024 | — |
| CORRESP | Letter to the SEC | Jan 26, 2024 | — |
| CORRESP | Letter to the SEC | Jan 26, 2024 | — |
| CORRESP | Letter to the SEC | Jan 25, 2024 | — |
| CORRESP | Letter to the SEC | Jan 25, 2024 | — |
| CORRESP | Letter to the SEC | Jan 24, 2024 | — |
| CORRESP | Letter to the SEC | Jan 24, 2024 | — |
| CORRESP | Letter to the SEC | Jan 18, 2024 | — |
| CORRESP | Letter to the SEC | Jan 18, 2024 | — |
| CORRESP | Letter to the SEC | Jan 16, 2024 | — |
| CORRESP | Letter to the SEC | Jan 16, 2024 | — |
| CORRESP | Letter to the SEC | Dec 26, 2023 | — |
| CORRESP | Letter to the SEC | Dec 26, 2023 | — |
| CORRESP | Letter to the SEC | Dec 21, 2023 | — |
| CORRESP | Letter to the SEC | Dec 21, 2023 | — |
| CORRESP | Letter to the SEC | Dec 21, 2023 | — |
| CORRESP | Letter to the SEC | Dec 21, 2023 | — |
| CORRESP | Letter to the SEC | Dec 20, 2023 | — |
| CORRESP | Letter to the SEC | Dec 20, 2023 | — |
| CORRESP | Letter to the SEC | Dec 20, 2023 | — |
| CORRESP | Letter to the SEC | Dec 20, 2023 | — |
| CORRESP | Letter to the SEC | Dec 14, 2023 | — |
| CORRESP | Letter to the SEC | Dec 14, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 13, 2023 | — |
| EFFECT | Filing | Nov 30, 2023 | — |
| CORRESP | Letter to the SEC | Nov 28, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 28, 2023 | — |
| EFFECT | Filing | Nov 30, 2022 | — |
| CORRESP | Letter to the SEC | Nov 28, 2022 | — |
| CORRESP | Letter to the SEC | Nov 28, 2022 | — |
| CORRESP | Letter to the SEC | Nov 15, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 4, 2022 | — |
| EFFECT | Filing | Jan 31, 2022 | — |
| CORRESP | Letter to the SEC | Jan 28, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 26, 2022 | — |
| EFFECT | Filing | Feb 3, 2021 | — |
| CORRESP | Letter to the SEC | Feb 1, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2021 | — |
| EFFECT | Filing | Dec 22, 2020 | — |
| CORRESP | Letter to the SEC | Dec 21, 2020 | — |
| CORRESP | Letter to the SEC | Dec 21, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 7, 2020 | — |
| DRS | Filing | Nov 30, 2020 | — |
| EFFECT | Filing | Oct 6, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 2, 2020 | — |
| CORRESP | Letter to the SEC | Oct 2, 2020 | — |
| C-TR | Filing | Apr 24, 2020 | — |
| EFFECT | Filing | Nov 7, 2019 | — |
| CERT | Filing | Nov 6, 2019 | — |
| CORRESP | Letter to the SEC | Nov 5, 2019 | — |
| CORRESP | Letter to the SEC | Nov 5, 2019 | — |
| 8-A12B | Form 8-a | Nov 5, 2019 | — |
| CORRESP | Letter to the SEC | Jul 16, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 10, 2019 | — |
| CORRESP | Letter to the SEC | Jun 28, 2019 | — |
| C-AR | Filing | Apr 30, 2019 | Dec 31, 2018 |
| UPLOAD | Letter from the SEC | Apr 24, 2019 | — |
| DRS | Filing | Mar 28, 2019 | — |
| 1-A-W | Form 1-a offering statement withdrawal | Mar 28, 2019 | — |
| 1-A/A | Filing | Oct 26, 2018 | — |
| 1-A/A | Filing | Oct 12, 2018 | — |
| 1-A/A | Filing | Sep 10, 2018 | — |
| 1-A | Filing | Jun 15, 2018 | — |
| C-U | Filing | Jun 15, 2018 | — |
| DOS | Filing | Apr 17, 2018 | — |
| C | Filing | Mar 13, 2018 | — |
Showing 86 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNSP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1729427
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.